Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Andrew Gengos Purchases 10,000 Shares

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CFO Andrew Gengos acquired 10,000 shares of Terns Pharmaceuticals stock in a transaction that occurred on Friday, June 27th. The stock was purchased at an average cost of $3.93 per share, with a total value of $39,300.00. Following the completion of the purchase, the chief financial officer owned 25,000 shares in the company, valued at $98,250. The trade was a 66.67% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Andrew Gengos also recently made the following trade(s):

• On Monday, June 16th, Andrew Gengos bought 5,000 shares of Terns Pharmaceuticals stock. The shares were acquired at an average cost of $3.95 per share, with a total value of $19,750.00.
• On Friday, June 13th, Andrew Gengos purchased 10,000 shares of Terns Pharmaceuticals stock. The stock was acquired at an average cost of $3.73 per share, for a total transaction of $37,300.00.

Terns Pharmaceuticals Stock Performance

Shares of TERN stock traded up $0.12 on Tuesday, hitting $3.85. 866,254 shares of the stock traded hands, compared to its average volume of 1,474,144. Terns Pharmaceuticals, Inc. has a twelve month low of $1.87 and a twelve month high of $11.40. The firm's 50-day moving average price is $3.39 and its two-hundred day moving average price is $3.80. The stock has a market capitalization of $336.26 million, a PE ratio of -3.53 and a beta of -0.11.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.03. On average, equities research analysts anticipate that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current fiscal year.

Analyst Ratings Changes

TERN has been the subject of several research reports. William Blair reaffirmed a "market perform" rating on shares of Terns Pharmaceuticals in a research note on Friday, March 21st. JMP Securities restated a "market outperform" rating and set a $20.00 target price on shares of Terns Pharmaceuticals in a report on Monday, April 21st. Finally, BMO Capital Markets cut their price target on Terns Pharmaceuticals from $26.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $15.63.

Institutional Trading of Terns Pharmaceuticals

Several institutional investors have recently made changes to their positions in TERN. Rhumbline Advisers grew its position in Terns Pharmaceuticals by 16.0% in the fourth quarter. Rhumbline Advisers now owns 97,892 shares of the company's stock worth $542,000 after acquiring an additional 13,479 shares during the period. Y Intercept Hong Kong Ltd lifted its stake in shares of Terns Pharmaceuticals by 84.1% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 67,002 shares of the company's stock valued at $371,000 after purchasing an additional 30,610 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Terns Pharmaceuticals by 15.4% during the 4th quarter. Bank of New York Mellon Corp now owns 186,308 shares of the company's stock worth $1,032,000 after purchasing an additional 24,930 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Terns Pharmaceuticals by 33.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 206,450 shares of the company's stock worth $1,144,000 after purchasing an additional 51,736 shares during the period. Finally, Candriam S.C.A. acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter worth about $11,933,000. Hedge funds and other institutional investors own 98.26% of the company's stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.